



Media Statement

March 15, 2021

Johnson & Johnson Confirms Agreement IDT Biologika

Janssen, the Pharmaceutical Companies of Johnson & Johnson, is pleased to confirm a short-term agreement with IDT Biologika GmbH ("IDT Biologika") to formulate and fill vials of our Janssen COVID-19 vaccine for up to 12 weeks as part of our global supply network. We appreciate the collaboration of IDT Biologika, Takeda Pharmaceutical Company and the Government of Germany for their roles in supporting our collective effort to end this global COVID-19 pandemic.

Since January 2020, we have been working directly with governments, health authorities and other companies to help end this pandemic. IDT Biologika is the tenth manufacturer to join our global supply network and this collaboration will further enable us to deliver our COVID-19 vaccine worldwide. We will continue to invest in collaborations so we can bring our full resources and best scientific minds to combat this pandemic.

###